Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03742037 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Viatris Innovation.
- Completed
- Registry status
- Phase 2
- Development phase
- 427
- Enrollment target
NCT03742037 is a Phase 2 study that has completed, run by Viatris Innovation. The registered enrollment target is 427 participants.
The verdict
NCT03742037, a Phase 2 study, has completed, sponsored by Viatris Innovation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 427 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).
Interventions
- DRUG Placebo
- DRUG Cenerimod 0.5 mg
- DRUG Cenerimod 1 mg
- DRUG Cenerimod 2 mg
- DRUG Cenerimod 4 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2022-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03742037
The ClinicalTrials.gov registry entry for NCT03742037 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 427 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viatris Innovation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03742037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03742037 about?
NCT03742037 is a clinical study titled "Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus". The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).
What is the current status of trial NCT03742037?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 427 participants. The study started on 2018-12-21. Estimated completion is 2022-08-25.
What interventions are being tested in trial NCT03742037?
The interventions under investigation include: Placebo (DRUG), Cenerimod 0.5 mg (DRUG), Cenerimod 1 mg (DRUG), Cenerimod 2 mg (DRUG), Cenerimod 4 mg (DRUG).
Who is sponsoring clinical trial NCT03742037?
This trial is sponsored by Viatris Innovation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.